Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Author(s) -
Ofri Mosenzon,
Itamar Raz,
Stephen D. Wiviott,
Meir Schechter,
Erica L. Goodrich,
Ilan Yanuv,
Aliza Rozenberg,
Sabina A. Murphy,
Thomas A. Zelniker,
Anna Maria Langkilde,
Ingrid GauseNilsson,
Martin Fredriksson,
Peter A. Johansson,
John Wilding,
Darren K. McGuire,
Deepak L. Bhatt,
Lawrence A. Leiter,
Avivit Cahn,
Jamie P. Dwyer,
Hiddo J.L. Heerspink,
Marc S. Sabatine
Publication year - 2022
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc22-0382
Subject(s) - medicine , dapagliflozin , timi , type 2 diabetes , post hoc analysis , diabetes mellitus , post hoc , kidney disease , endocrinology , myocardial infarction , thrombolysis
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom